Premium
Evaluation of a Single Intra‐Articular Injection of Autologous Protein Solution for Treatment of Osteoarthritis in a Canine Population
Author(s) -
Wanstrath Audrey W.,
Hettlich Bianca F.,
Su Lillian,
Smith Ashley,
Zekas Lisa J.,
Allen Matthew J.,
Bertone Alicia L.
Publication year - 2016
Publication title -
veterinary surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.652
H-Index - 79
eISSN - 1532-950X
pISSN - 0161-3499
DOI - 10.1111/vsu.12512
Subject(s) - medicine , lameness , osteoarthritis , placebo , saline , elbow , visual analogue scale , brief pain inventory , randomized controlled trial , horse , population , physical therapy , anesthesia , surgery , chronic pain , paleontology , alternative medicine , environmental health , pathology , biology
Objective To evaluate the safety and efficacy of an intra‐articular injection of autologous protein solution (APS) for treatment of canine osteoarthritis (OA). Study Design Prospective, randomized, blinded, placebo‐controlled pilot clinical trial. Animals Client‐owned dogs with single limb lameness because of OA in a stifle or elbow joint (n=21). Methods Lame dogs, confirmed with OA by physical and lameness examination and imaging, were randomly assigned to control or treatment groups. Owners, blinded to treatment, scored pain (University of Pennsylvania Canine Brief Pain Inventory) and lameness severity (Hudson Visual Analogue Scale [HVAS]). Weight‐bearing was assessed by kinetic gait analysis. Dogs were injected intra‐articularly with APS (treatment group) or saline solution (control group). Evaluations were performed before injection, and 2 and 12 weeks post‐injection. Results Compared to pretreatment values, APS treatment data showed a significant improvement in week 12 pain scores (improved 25.6% over baseline), lameness scores (improved 15% over baseline) and peak vertical force (PVF; N/kg; increased 14.9% of baseline), as well as vertical impulse (Ns/kg) and PVF normalized to stance time (N/kg/s). Control group dogs improved at week 2 in owner assigned indices, but not force plate values and had no significant improvement in scores or force plate values from pretreatment values at 12 weeks. Conclusion APS injection reduced pain and lameness scores and increased weight‐bearing associated with the OA‐affected joint in dogs at 12 weeks providing preliminary evidence that APS therapy may be beneficial in the treatment of OA in dogs and supporting pursuit of additional studies.